Background:

Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease (CKD) worldwide and has a direct impact on cardiovascular risk and mortality in patients with diabetes mellitus (DM). Finerenone, a selective mineralocorticoid receptor (MRA) antagonist, has been described in several recent studies as a drug that contributes to slowing the progression of CKD and reducing cardiovascular risk, with an adequate safety profile.

Purpose:

To carry out a review of the literature on the impact of finerenone on the progression of renal damage and cardiovascular risk in patients with DKD.

Methodology:

A systematic search were carried out in various sources: PubMed (Medline, United States Library of Congress), Science Direct, Scopus, Embase and Lilacs; the search was restricted to references in Spanish and English, with no limits on publication date. The following keywords in the English language were used: diabetic renal disease, chronic kidney disease, diabetes mellitus, spironolactone, eplerenone, finerenone, mineralocorticoid receptor antagonist and their corresponding Spanish versions.

Results:

The references found in the search were reviewed among the different authors to subsequently proceed to prepare the document.

Conclusions:

Finerenone is a drug that provides cardio and nephroprotection in patients with DKD albuminuric phenotype.

        · resumen en Español     · texto en Español     · Español ( pdf )